DALLAS, Dec. 19, 2012 /PRNewswire/ -- X-Change Corp (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is cannabis and hemp based extracts targeting Medical Cannabis, Cosmeceutical and Neutroceuticals and Social Usage solutions through multiple Phytiva Brand Product Lines. The Company issues a stronger outlook for 2013 based on new Phytiva Product Lines for the Medical Cannabis Industry as a whole. These new Phytiva Product Lines will be launched with Cannabis based formulations through Medical Cannabis dispensaries, Cannabis laboratories, and individual legal State grow operations on a State by State approved basis.
The Company is working with approved partners operating in legal jurisdictions under State approved permits developing its newest Cannabis based Phytiva Product lines that have identified over a dozen ailments that we believe that our products will be the superior choice on the market. These ailments include cancer, arthritis, influenza, HIV/ AIDS, PTSD and many more.
The global markets that the Phytiva product lines are targeting is enormous. The Cancer industry is estimated at $300 billion globally by 2025, the HIV Therapeutics market is estimated to be $21.8 Billion by 2018. This is in addition to the PTSD Therapeutics market which was worth $1.3 Billion in 2011. Recently, a cure for Cancer, if realized, is estimated to be worth over $ 1 trillion. Social use has just become available in Washington State and Oregon, many numbers are reported very high, but the Company is awaiting official word.
X-Change Corporation through its Phytiva Brand Product line intends to release product formulations that include high-level CBD's and variations of THC, CBD's, and other cannabinoid elements. These formulations will be in addition to the existing development of the hemp extract based products forthcoming in 2013.
Industry estimates predict that approximately 3% of the overall populations are cannabis patients. 18 states are now operating under some version of a state legal program with full recreational use in Colorado and Washington. Another dozen states are expected to legalize by 2016 with a national legalization approval shortly thereafter this is in addition to several countries that are now also moving in the same direction.
Robert J Kane, President stated "X-Change Corporation is much more than just an over the counter hemp extract based products. It is our intention to take advantage of all markets we have access to with our products and services we have at our fingertips. I look forward to being more than just a participant in these markets, by capturing an impressive amount of market share.
Phytiva is the newly launched brand that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a hemp-based product line, utilizing the unique and potent benefits of the hemp plant. Phytiva's revolutionary formulations target not just the symptom, but also the cause. Hemp is the ideal basis for healing solutions and has been utilized for centuries, as skin responds extremely well to its properties.
Phytiva strives to be one of the quintessential Cosmeceuticals and Nutraceuticals brands in the world. As cosmetics and nutrition are personal, over-the-counter markets, they continuously evolve with the introduction of new formulations and products, creating a multibillion-dollar global market. The company believes that Phytiva will capture a substantial and highly-profitable portion of that market, as Phytiva becomes a household name.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE X-Change Corp